EPAS1 and nonpapillary renal cell carcinoma: Targeting the HIF2-Vascular endothelial growth factor (VEGF) axis, multiple VEGF inhibitors are approved for the treatment of ccRCC, and a HIF2α inhibitor has advanced to phase 3 development for this disease (Choueiri and Kaelin, 2020).